Latest Attention-deficit hyperactivity disorder controversies Stories
Children who are mixed-handed, or ambidextrous, are more likely to have mental health, language and scholastic problems in childhood than right- or left-handed children, according to a new study published today in the journal Pediatrics.The researchers behind the study, from Imperial College London and other European institutions, suggest that their findings may help teachers and health professionals to identify children who are particularly at risk of developing certain problems.Around one...
PHILADELPHIA, Dec. 21 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced the launch of its newest online Attention-Deficit/Hyperactivity Disorder (ADHD) resource, the ADHD Support Twitter(TM) page (http://twitter.com/adhdsupport), derived from the Shire award-winning online educational resource, ADHDSupport.com. The social networking service Twitter, estimated to reach approximately six million unique monthly visitors,...
University of Oregon-developed program passes vigorous testing among diverse elementary student populationA school-based behavioral intervention program developed under a federal grant in the mid-1990s at the University of Oregon, already in widespread use, now has shown real value on a complex stage, scoring robust improvements among at-risk elementary students in the predominantly minority Albuquerque, N.M., school district.The program First Step to Success was developed to target...
Children exposed prenatally to tobacco smoke and during childhood to lead face a particularly high risk for ADHD, according to research done at Cincinnati Children's Hospital Medical Center.The study estimates that up to 35 percent of ADHD cases in children between the ages of 8 and 15 could be reduced by eliminating both of these environmental exposures. This could translate into up to 800,000 children"Tobacco and lead exposure each have their own important adverse effect," says...
Primary objective of the study was to evaluate the safety of coadministration of INTUNIV with stimulantsShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIVâ„¢ (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate...
PHILADELPHIA, Nov. 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication...
PHILADELPHIA, Nov. 9 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the...
LAS VEGAS, Nov. 4 /PRNewswire/ -- New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that demonstrate a significant treatment effect on attention at one hour and through 12.5 hours in children with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a common and treatable medical condition characterized by inattention, hyperactivity and impulsivity(1) that is estimated to affect...
NEW YORK, Nov. 4 /PRNewswire/ -- Global public relations leader Porter Novelli announced today that it received the Gold Award from Medical Marketing & Media for best unbranded TV advertisement/campaign. The award honored the agency's work, done on behalf of its Shire Pharmaceuticals client, on the public service campaign titled "Adult ADHD is Real." In collaboration with Attention-Deficit/Hyperactivity Disorder (ADHD) advocacy groups ADHD Coaches Organization (ACO), Attention Deficit...
PLYMOUTH MEETING, Pa., Nov. 2 /PRNewswire/ -- BioBehavioral Diagnostics Company announced today that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009. Calvin R. Sumner, M.D., the company's Chief Medical Officer and Senior Vice President of Clinical...
